CRTH2 antagonists in asthma: current perspectives

Dave Singh, Arjun Ravi, Thomas Southworth Division of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK Abstract: Chemoattr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singh D, Ravi A, Southworth T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	CRTH2 Eosinophilic asthma Prostaglandin D2 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/af653f6e2cb94424bf414501e6e6785e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af653f6e2cb94424bf414501e6e6785e
record_format	dspace
spelling	oai:doaj.org-article:af653f6e2cb94424bf414501e6e6785e2021-12-02T01:54:18ZCRTH2 antagonists in asthma: current perspectives1179-1438https://doaj.org/article/af653f6e2cb94424bf414501e6e6785e2017-12-01T00:00:00Zhttps://www.dovepress.com/crth2-antagonists-in-asthma-current-perspectives-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Dave Singh, Arjun Ravi, Thomas Southworth Division of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK Abstract: Chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) binds to prostaglandin D2. CRTH2 is expressed on various cell types including eosinophils, mast cells, and basophils. CRTH2 and prostaglandin D2 are involved in allergic inflammation and eosinophil activation. Orally administered CRTH2 antagonists are in clinical development for the treatment of asthma. The biology and clinical trial data indicate that CRTH2 antagonists should be targeted toward eosinophilic asthma. This article reviews the clinical evidence for CRTH2 involvement in asthma pathophysiology and clinical trials of CRTH2 antagonists in asthma. CRTH2 antagonists could provide a practical alternative to biological treatments for patients with severe asthma. Future perspectives for this class of drug are considered, including the selection of the subgroup of patients most likely to show a meaningful treatment response. Keywords: CRTH2, clinical trial, eosinophilic asthma, prostaglandin D2Singh DRavi ASouthworth TDove Medical PressarticleCRTH2Eosinophilic asthmaProstaglandin D2Therapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 165-173 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	CRTH2 Eosinophilic asthma Prostaglandin D2 Therapeutics. Pharmacology RM1-950
spellingShingle	CRTH2 Eosinophilic asthma Prostaglandin D2 Therapeutics. Pharmacology RM1-950 Singh D Ravi A Southworth T CRTH2 antagonists in asthma: current perspectives
description	Dave Singh, Arjun Ravi, Thomas Southworth Division of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK Abstract: Chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) binds to prostaglandin D2. CRTH2 is expressed on various cell types including eosinophils, mast cells, and basophils. CRTH2 and prostaglandin D2 are involved in allergic inflammation and eosinophil activation. Orally administered CRTH2 antagonists are in clinical development for the treatment of asthma. The biology and clinical trial data indicate that CRTH2 antagonists should be targeted toward eosinophilic asthma. This article reviews the clinical evidence for CRTH2 involvement in asthma pathophysiology and clinical trials of CRTH2 antagonists in asthma. CRTH2 antagonists could provide a practical alternative to biological treatments for patients with severe asthma. Future perspectives for this class of drug are considered, including the selection of the subgroup of patients most likely to show a meaningful treatment response. Keywords: CRTH2, clinical trial, eosinophilic asthma, prostaglandin D2
format	article
author	Singh D Ravi A Southworth T
author_facet	Singh D Ravi A Southworth T
author_sort	Singh D
title	CRTH2 antagonists in asthma: current perspectives
title_short	CRTH2 antagonists in asthma: current perspectives
title_full	CRTH2 antagonists in asthma: current perspectives
title_fullStr	CRTH2 antagonists in asthma: current perspectives
title_full_unstemmed	CRTH2 antagonists in asthma: current perspectives
title_sort	crth2 antagonists in asthma: current perspectives
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/af653f6e2cb94424bf414501e6e6785e
work_keys_str_mv	AT singhd crth2antagonistsinasthmacurrentperspectives AT ravia crth2antagonistsinasthmacurrentperspectives AT southwortht crth2antagonistsinasthmacurrentperspectives
_version_	1718402861554991104

CRTH2 antagonists in asthma: current perspectives

Ejemplares similares